Cancer Center Support Grant

描述（由申请人提供）：本更新申请为希望之城综合癌症中心的NCI癌症中心支持基金申请第25至29年的资金。中心现有五个研究项目：一个基础研究项目（癌症生物学，CB）；三个临床/转化研究项目（发展癌症治疗学，DCT，癌症免疫治疗学，Cl，恶性血液学，HM）；以及一个人口研究项目（癌症控制与人口科学，CCPS）。12个共享资源支持会员的科学活动，包括两个新核心（小动物成像；临床免疫生物学相关研究实验室）。提出了三个发展核心（高通量筛选、合成与生物高分子化学、调查研究）。在之前的项目期间，会员人数增长了45%，招募了37名新的正式会员，其中包括几位关键的高级领导（Richard Jove博士，副主任；R. Figlin医学博士，临床研究副主任）。其他关键的领导职位也通过内部任命填补（Smita Bhatia，医学博士，公共卫生硕士，人口研究副主任；Joyce Niland，博士，信息科学副主任；Yun Yen，医学博士，博士，转化研究副主任）。由于我们的项目重组，招聘和基础设施发展，我们现在相信我们有一个中心，我们的五个项目代表了一个连续体，在这个连续体中，基础科学项目，CB和一个临床项目，DCT的基础和转化研究可以与所有三个临床项目（DCT, Cl， HM）的I期和II期临床协议以及人口科学项目（CCPS）的生存和症状管理的后续研究联系起来。所有这些活动都是通过一个中心和机构的基础设施来实现的，这个基础设施以一种非常合作的方式支持生物和小分子方法治疗癌症的基础和转化研究。这种相互作用导致了该中心的第一个孢子，淋巴瘤；最近的W.M.凯克基金会奖；还有8个大型的，多名研究者的奖励。在下一个资助期内，我们将以这些成就为基础，使希望之城综合癌症中心在其发展中迈出下一步：将更多的实验室发现转化为创新的临床试验，并开发基于疾病的研究项目。自上次竞争性拨款审查以来，该中心项目的82名正式成员和90名准成员已经发表了1001篇文章、书籍章节等。其中28%是方案内出版物，22%是方案间出版物。

DESCRIPTION (provided by applicant): This renewal application requests funding for the 25th through 29th years of the NCI Cancer Center Support Grant of the City of Hope Comprehensive Cancer Center. The Center now has five research programs: one basic research Program (Cancer Biology, CB); three clinical/translational research Programs (Developmental Cancer Therapeutics, DCT; Cancer Immunotherapeutics, Cl; Hematologic Malignancies, HM); and one population research program (Cancer Control and Population Sciences, CCPS). Twelve shared resources support the scientific activities of the members, including two new cores (Small Animal Imaging; Clinical Immunobiology Correlative Studies Laboratory). Three developing cores are proposed (High Throughput Screening; Synthetic & Biopolymer Chemistry; Survey Research). Membership has grown by 45% in the preceding program period with the recruitment of 37 new Full Members, including several key senior leaders (Richard Jove, PhD, Deputy Director; R. Figlin, MD, Associate Director [AD] for Clinical Research). Other key leadership positions have also been filled through internal appointments (Smita Bhatia, MD, MPH, AD for Population Research; Joyce Niland, PhD, AD for Information Sciences; and Yun Yen, MD, PhD, AD for Translational Research). As a result of our program restructuring, recruitment and infrastructure development, we now believe we have a Center where our five Programs represent a continuum in which basic and translational studies in the basic science Program, CB, and one clinical Program, DCT, can be linked to Phase I and II clinical protocols in all three clinical programs (DCT, Cl, HM) and follow-up studies in survivorship and symptom management in the population sciences program (CCPS). All these activities are made possible by a Center and Institutional infrastructure that supports basic and translational research in biological and, now, small molecule approaches to cancer in an extraordinarily collaborative fashion. Such interaction has resulted in the Center's first SPORE, in lymphoma; a recent W.M. Keck Foundation award; and the renewal of eight large, multi-investigator awards. During the next funding period, we will build on these achievements so that the City of Hope Comprehensive Cancer Center takes the next step in its evolution: translating more laboratory discoveries into innovative clinical trials and developing disease-based research programs. The 82 Full Members and 90 Associate Members of the Center Programs have published 1001 articles, book chapters, etc., since the last competitive grant review. Of these, 28% are intraprogrammatic and 22% are interprogrammatic publications.